BENITIONSClinical Trial Intelligence

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Фаза 3 Идёт, набор закрыт NCT00644228

ЗаболеваниеDS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
ФазаФаза 3
СпонсорNational Cancer Institute (NCI)
СтатусИдёт, набор закрыт
Участники525 участн.
ВмешательствоBortezomib, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide
Дата начала28.07.2008
Дата завершения5.11.2015
Публикация результатов6.07.2017

Кратко

This randomized phase III trial studies lenalidomide, dexamethasone, and bortezomib to see how well it works compared to dexamethasone and lenalidomide alone in treating patients with previously untreated multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the cancer. It is not yet known whether lenalidomide and dexamethasone is more effective with or without bortezomib in treating multiple myeloma.

Progression-free Survival

From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 6 years · Months

Arm I (Dexamethasone and Lenalidomide)30 Months
Arm II (Dexamethasone, Lenalidomide, Bortezomib)43 Months
p-value0.0018
Hazard Ratio (HR)0.712 (95% CI 0.560–0.906)

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.